Antenne Médicale des Ecoles Militaires de Santé de Lyon-Bron (EMSLB)
Bron, 69675, France
NCT Number: NCT04516928
Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission is by droplet route, with an R0 of approximately 3.
Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions.
Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced.
During the period of containment, the majority of students from the Lyon-Bron Military Medical Schools were sent as reinforcement in Army Training Hospitals and in the Military Reanimation Unit (Mulhouse). Some students developed symptomatic forms of SARS-Cov-2 infection, documented by positive PCR, during Operation Resilience or on their return from the mission.
The Lyon-Bron Military Medical Schools staff, exposed both to the initial phase of the epidemic and to national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Bron, 69675, France
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.
Time frame: Day 0
The proportion of anti-SARS-CoV2 seropositive participants will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0.
Time frame: Day 0
The proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants) will be determined. COVID-19 symptoms will be measured using a questionnaire.
Time frame: Day 0
Correlation coefficient between medical risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Time frame: Day 0
Correlation coefficient between epidemiological risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Time frame: Day 0
Correlation coefficient between social risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Direction Centrale du Service de Santé des Armées
Other
Acronym: SeroCovEms
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04510194
COVID-19, Coronaviridae Infections
Sylmar, California, United States
View Trial DetailsNCT04895475
COVID-19, Coronaviridae Infections
Cincinnati, Ohio, United States
View Trial DetailsNCT04885452
COVID-19, Coronaviridae Infections
Agen, France
View Trial DetailsNCT04865237
COVID-19, Corona Virus Infection
London, United Kingdom
View Trial Details